title: Aerosolized iloprost therapy could not replace long-term IV epoprostenol (prostacyclin) administration in severe pulmonary hypertension.
abstract: OBJECTIVE
  To switch patients with severe pulmonary hypertension and previous life-threatening catheter-related complications from long-term IV epoprostenol therapy to aerosolized iloprost therapy.
  
  
  METHODS
  Open, uncontrolled trial.
  
  
  METHODS
  Medical ICU of a university hospital.
  
  
  METHODS
  Two patients with primary pulmonary hypertension and one patient with pulmonary hypertension after surgical closure of atrial septal defect (mean pulmonary artery pressure > or =50 mm Hg). All were classified as New York Heart Association class II under treatment with continuous IV epoprostenol for 4 years.
  
  
  METHODS
  Stepwise reduction of IV epoprostenol (1 ng/kg/min steps every 3 to 10 h) during repeated inhalations of aerosolized iloprost (150 to 300 microg/d with 6 to 18 inhalations/d). Continuous pulmonary and systemic arterial monitoring were performed.
  
  
  RESULTS
  Aerosolized iloprost reduced pulmonary artery pressure by 49%, 49%, and 45%, respectively, and increased cardiac output by 70%, 75%, and 41% in the three patients. The effect lasted for 20 min and was similar at different doses of IV epoprostenol. Persistent treatment change to inhaled iloprost could not be achieved because all patients developed signs of right heart failure. After termination of iloprost inhalations, return to standard epoprostenol therapy led to clinical and hemodynamic restoration.
  
  
  CONCLUSIONS
  Although aerosolized iloprost demonstrated short-term hemodynamic effects, it could not be utilized as alternative chronic vasodilator in patients with severe pulmonary hypertension.
authors.affiliation: Department of Internal Medicine IV, University of Vienna, Allgemeines Krankenhaus, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Schenk
authors.forename: V
authors.initials: V
authors.lastname: Petkov
authors.forename: C
authors.initials: C
authors.lastname: Madl
authors.forename: L
authors.initials: L
authors.lastname: Kramer
authors.forename: M
authors.initials: M
authors.lastname: Kneussl
authors.forename: R
authors.initials: R
authors.lastname: Ziesche
authors.forename: I
authors.initials: I
authors.lastname: Lang
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D000336:Aerosols; D002302:Cardiac Output / Q000187:drug effects; D003422:Critical Care; D011464:Epoprostenol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D016285:Iloprost / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008134:Long-Term Care; D008875:Middle Aged; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000336:Aerosols; D011464:Epoprostenol; D016285:Iloprost